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Control of gene expression through the 
nonsense-mediated RNA decay pathway
Andrew Nickless1†, Julie M. Bailis2† and Zhongsheng You1* 
Abstract 
Nonsense-mediated RNA decay (NMD) was originally discovered as a cellular surveillance pathway that safeguards 
the quality of mRNA transcripts in eukaryotic cells. In its canonical function, NMD prevents translation of mutant 
mRNAs harboring premature termination codons (PTCs) by targeting them for degradation. However, recent stud-
ies have shown that NMD has a much broader role in gene expression by regulating the stability of many normal 
transcripts. In this review, we discuss the function of NMD in normal physiological processes, its dynamic regulation 
by developmental and environmental cues, and its association with human disease.
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Background
Nonsense-mediated RNA decay (NMD) is an essential 
RNA quality control and gene regulatory mechanism that 
is conserved among eukaryotes [1–9]. NMD safeguards 
the quality of the transcriptome and maintains cellular 
homeostasis by eliminating transcripts that harbor pre-
mature termination codons (PTCs). PTCs can arise from 
errors in nucleic acid metabolism, such as genetic muta-
tions or defects in splicing or transcription. In addition, 
PTCs may also form during mRNA synthesis from nor-
mal gene structures, including from programmed recom-
bination. In its canonical role, NMD prevents translation 
of transcripts that might produce C-terminally truncated 
proteins with reduced or aberrant function.
NMD also targets non-mutant transcripts, and its 
regulation of normal gene expression impacts a wide 
range of physiological processes including cell differen-
tiation, response to stress and development of disease. 
Recent estimates suggest that NMD-mediated degrada-
tion affects up to 25% of transcripts, either directly or 
indirectly in certain cellular milieus [1, 10, 11]. Although 
the overall process of NMD is conserved for both mutant 
and non-mutant transcripts, the signals that trigger 
NMD or its inhibition vary according to the specific tar-
get and biological context.
In this review we focus on the function and impact of 
NMD on normal gene expression in mammals. We out-
line the NMD process and highlight the known roles for 
NMD in normal physiology, with a particular emphasis 
on its function as a gene regulatory mechanism and its 
dynamic regulation by environmental and developmental 
signals. We conclude with an overview of the impact of 
NMD dysregulation on human disease and discuss the 
potential of treating genetic and neurological disorders 
and cancer by manipulating NMD activity.
Overview of the NMD pathway
First discovered in yeast and then extensively studied in 
Caenorhabditis elegans, Drosophila, mouse, human cells, 
and other model systems, NMD is a RNA surveillance 
pathway that acts at the interface between transcrip-
tion and translation [10, 12–15]. NMD must accurately 
distinguish a PTC from a normal stop codon on an 
mRNA and then recruit and activate enzymes to destroy 
the transcript. There are two main models to explain 
how transcripts are identified as targets for NMD. The 
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exon-junction complex (EJC) model proposes that 
EJC—a large multi-protein assembly deposited  ~20–24 
bases upstream of an exon–exon junction as a result of 
pre-mRNA splicing—acts as a second signal to mark an 
upstream stop codon as a PTC [16–29]. During transla-
tion, ribosomes scan the mRNA and will pause at a stop 
codon. If an EJC is present more than 50–55 bases down-
stream of the stop codon, the protein kinase SMG1, its 
substrate Upf1, a ATPase/helicase, and eukaryotic poly-
peptide release factors eRF1 and eRF3 are then recruited 
to form a complex—the SURF complex—on the mRNA. 
Phosphorylation of UPF1 by SMG1 leads to the recruit-
ment of SMG5, SMG6 and SMG7 via phospho-specific 
interactions [30, 31]. After recruitment, SMG5 and 
SMG7 promote RNA decapping and deadenylation by 
recruiting factors such as DCP1a and POP2, leading to 
the exposure of the transcript ends to cellular exonucle-
ases [32–39]. SMG6, which has endonuclease activity, 
provides a second mechanism for initiation of mRNA 
decay by cleaving transcripts internally near the PTC, 
generating two unprotected RNA ends that are further 
degraded by cellular nucleases [40–43].
The second model for NMD posits that the abnormally 
long 3′ untranslated region (UTR) downstream of a PTC 
acts as a second signal to promote PTC recognition. 
While the molecular mechanism of this model is less well 
defined, it has been proposed that accumulation of UPF1 
as well as other regulatory elements in the 3′ UTR medi-
ates the recruitment of other NMD factors and the initia-
tion of mRNA decay [44–47]. For additional information 
about the mechanisms of PTC recognition, readers are 
directed to a number of recent reviews [13, 48–50].
A debate remains about where NMD takes place in 
the cell. NMD inherently relies on the translation pro-
cess, which normally occurs in the cytoplasm. However, 
some investigators have proposed that translation can 
also take place in the cell nucleus [51–53]. Several stud-
ies suggest that NMD is associated with the nucleus or 
nuclear fraction. For example, levels of PTC-contain-
ing triosephosphate isomerase (TPI) and mouse major 
urinary protein (MUP) transcripts were specifically 
reduced in the nuclear fraction [54–57]. NMD-medi-
ated degradation of the TCRβ transcript can also take 
place in purified nuclei [58]. Several other nonsense 
reporter mRNAs also appear to be targeted by NMD in 
the nucleus [51, 59–64]. The idea of PTC recognition in 
the nucleus is also consistent with the existence of non-
sense-associated altered splicing (NAS), a NMD-related 
nuclear pathway that also requires PTC recognition 
[65]. However, the claims of nuclear NMD and transla-
tion remain controversial as other lines of evidence sug-
gest that NMD is primarily a cytoplasmic process [25]. 
Indeed, alternative interpretations of the nuclear NMD 
data are possible, including the possibility that NMD 
occurs during nuclear export, of which there is some 
evidence [66].
Role of NMD and its regulation in normal 
physiological processes
Bioinformatics analysis of EST databases and RNA 
sequencing data in cells where NMD is disrupted have 
clearly demonstrated that NMD has a widespread effect 
on gene expression [10, 67, 68]. This realization has led 
to the identification of numerous putative NMD target 
mRNAs, based on characteristics such as PTCs or long 
3′ UTRs and an observed increase in the stability and/or 
levels of transcripts after NMD suppression [1, 4, 5, 11, 
69–75].
Multiple mechanisms exist to generate PTCs in tran-
scripts of normal genes (Fig. 1). Alternative splicing gen-
erates diversity in mRNA isoforms but can also lead to 
formation of PTCs that target transcripts for NMD. For 
instance, the RNA binding protein polypyrimidine tract 
binding protein 1 (PTBP1) can repress splicing of exon 11 
of its own mRNA, leading to NMD of the transcript [76]. 
As such, PTBP1 negatively regulates its own expression. 
Human arginine–serine rich (SR) splicing factors have 
also been shown to be regulated by alternative splicing 
coupled to NMD [77, 78]. This so-called unproductive 
splicing and translation (RUST) represents an autoregu-
latory mechanism that controls the levels of splicing fac-
tors and other RNA binding proteins [77–81]. The use of 
alternative transcription initiation sites can also generate 
mRNA isoforms with a stop codon upstream of a splice 
junction, resulting in NMD [82]. Programmed ribosomal 
frameshifting (PRF)—which can potentially occur in up 
to 8–12% of genes—is another mechanism that can cre-
ate a PTC, leading to NMD [83–86]. Stop codons that 
trigger NMD can also form if the primary coding region 
of an mRNA is preceded by an upstream open reading 
frame (uORF) [87, 88]. Transcriptome analysis indicates 
that long 3′ UTRs are among the most common features 
of NMD targets, although 3′ UTR length per se is not 
considered a reliable predictor of NMD of a given tran-
script [29, 44–46, 74, 88–91].
Transcripts encoding selenoproteins comprise another 
interesting class of NMD targets. A UGA codon normally 
signals a stop to translation but can be redefined to code 
for the amino acid selenocysteine in a high selenium 
environment [92]. If selenocysteine is incorporated in the 
last exon of a transcript it generally evades NMD, while 
if selenium is not abundant, these transcripts will be 
degraded via NMD if their stop codon resides upstream 
of an exon–exon junction [93, 94]. This regulatory mech-
anism enables cells to respond to alterations in levels of 
the essential trace element selenium. Therefore, while 
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some NMD targets—such as those encoding selenopro-
teins or splicing factors—have been well characterized, 
the validation of other putative NMD targets is ongoing, 
as is the understanding of the consequences of NMD-
induced regulation of gene expression.
There are many examples where normal physiologi-
cal processes employ NMD to regulate gene expression 
(Table 1). As an example of the essential nature of NMD 
for normal cellular processes, knockouts of Smg1, Smg6, 
Upf1, or Upf2 have been shown to cause embryonic lethal-
ity in mice [1–4, 6]. NMD has also been shown to play a 
central role in the development and differentiation of spe-
cific cell types through regulation of gene expression.
During lymphocyte development, cells undergo a series 
of programmed genomic rearrangements to assemble 
immunoglobin and T cell receptor (TCR) genes. Two-
thirds of these rearrangement events yield unproductive 
gene products harboring PTCs, whose clearance requires 
NMD [5, 95, 96]. Consistent with this observation, condi-
tional ablation of NMD in T-cells significantly increased 
the abundance of these nonsense TCR transcripts, result-
ing in apoptotic cell death [5]. Interestingly, thymocyte 
development could be restored by introducing a com-
plete TCRβ sequence that prevents the accumulation of 
nonsense counterparts, indicating that removal of the 
mutant transcripts by NMD is key to the survival of these 
cells [97]. However, conditional knockout of Upf2 had 
minimal effects on mature T cells, perhaps because T cells 
naturally downregulate NMD as part of the differentiation 
process [5]. In the myeloid lineage, the LMNB1 mRNA is 
specifically downregulated by NMD during granulopoie-
sis due to programmed intron retention. Importantly, this 
regulation of LMNB1 mRNA is required for normal dif-
ferentiation of granulocytes [98].
NMD
Regulation of 
Gene ExpressionRNA Quality Control
Aberrant Transcripts Normal Transcripts
Genetic 
Mutations
Aberrant 
Splicing
Inaccurate 
Transcription
uORF
Alternative 
Splicing
Intron
Programmed 
Ribosomal 
Frameshifting
Frameshifting Signal
PTC
No PTC
Fig. 1 NMD functions both in RNA surveillance and in gene regulation. Several features of mRNA transcripts can mark the transcripts as substrates 
for degradation by NMD. Green boxes, exons; lines, introns; potential splicing events are shown by blue or purple lines; genetic mutations and tran-
scriptional aberrations are denoted with stars. The translation start site (ATG) is marked by arrows and stop codons are marked by red circles
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Similar to the hematopoietic system, embryonic stem 
cells (ESCs) rely on NMD for their proliferation, while 
their differentiation is associated with downregulation 
of NMD activity [99, 100]. NMD influences stem cell dif-
ferentiation by regulating the signaling of two key growth 
factors, TGFβ and BMP [100]. Ablation of NMD by 
SMG6 knockout in mouse ESCs prevented cellular differ-
entiation, and re-expression of wild type but not mutant 
SMG6 restored proper differentiation [6]. Knockdown 
of other NMD factors caused a similar phenotype [6]. 
Prolonged, elevated expression of NMD-regulated pluri-
potency genes, such as c-Myc, underlies the inability of 
NMD-deficient ESCs to differentiate [6].
A number of studies have also revealed connections 
between NMD and proper development of the nervous 
system [90, 101–109]. In mammals, UPF3B expression is 
altered during brain development, and UPF3B mutants 
with impaired NMD function inhibit proper neurite out-
growth [105, 107]. Neuronal development is also com-
promised when UPF3B is downregulated with shRNA or 
when NMD is inhibited with the compound Amlexanox 
[105, 107]. NMD also functions to limit the expression 
of Robo3.2 in commissural neurons, which is required 
for proper axonal migration during development [109]. 
NMD components such as SMG1, UPF1 and UPF2 can 
localize to axonal growth cones in neurons, consist-
ent with the idea that NMD modulates gene expression 
locally in these structures [109]. During the process of 
neurogenesis, a regulatory circuit is activated in differ-
entiating neurons whereby expression of miR-128 targets 
mRNAs of several NMD factors for translational repres-
sion [90]. This results in NMD attenuation and upregula-
tion of NMD target genes, many of which foster proper 
neuronal development [90].
Nonsense-mediated RNA decay also can impact gene 
expression in mature neurons, however. Ablation of the 
EJC factor eIF4AIII in mature neurons results in altered 
expression of critical factors such as ARC, leading to 
increased synaptic strength [108]. During seizure, when 
neuronal activity is aberrant, the RNA splicing pro-
tein NOVA regulates insertion of cryptic exons into the 
mRNA of a number of neuronal factors, leading to NMD 
of these transcripts [110]. Together, these findings high-
light the importance of NMD in the development and 
function of the nervous system.
In developing muscle cells, NMD activity is attenuated 
as myoblasts differentiate to myotubes. During myogen-
esis, gene expression can be downregulated by NMD or 
by a related pathway, Staufen-mediated mRNA decay 
(SMD). SMD is increased in myoblasts due to the upreg-
ulation of the STAU1 (Staufen homolog) protein, which 
binds its cognate sites in the 3′ UTR of target mRNAs 
[111]. STAU1 competes with UPF1 for binding to UPF2, 
which functions in both NMD and SMD [112, 113]. 
This competition leads to inhibition of UPF2-dependent 
NMD and increased expression of the NMD target myo-
genin that promotes myogenesis [112].
Interactions of cells with external factors such as 
viruses can also be modulated by NMD. Robust NMD 
activity targets certain viral RNAs harboring NMD-
inducing features to suppress expression of viral proteins 
and limit viral titer in host cells [114, 115]. However, 
some viruses possess mechanisms to co-opt the NMD 
process for their own benefit. For example, it has been 
found that the RNA-binding proteins tax and rex, 
expressed by the human T-cell leukemia virus type-1 
(HTLV-1), stabilize both viral RNAs and host RNAs that 
would normally be targets for NMD [116, 117]. An ele-
ment in the 3′ UTR of the Rous sarcoma virus also ren-
ders the viral RNA insensitive to host NMD, possibly by 
inhibiting the capacity of UPF1 to initiate NMD [118, 
119]. As another example, hepatitis C infection triggers 
inactivation of NMD by binding and sequestering WIBG/
PYM, a protein required for recycling of the EJC [120].
Recent studies suggest that NMD controls not only 
the levels of mRNAs, but also that of long non-coding 
RNAs (lncRNAs). While the majority of the genome is 
transcribed into RNA, only about 2% of the genome has 
been shown to code for proteins [121, 122]. LncRNAs are 
a prominent class of RNA molecules that have important 
roles in cellular processes, including modifying chroma-
tin, regulating transcription, altering mRNA stability, and 
influencing translation [123, 124]. A subset of lncRNAs 
have been shown to be associated with the translation 
machinery—sometimes producing detectable micropep-
tides—and about 17% of lncRNAs were found to be tar-
gets of NMD [125–130]. While the biological significance 
of this regulation remains to be defined, the fact that so 
many lncRNA transcripts are targeted by NMD suggests 
that NMD plays a central role in regulating the func-
tions of lncRNAs and their corresponding micropeptide 
products.
Dynamic regulation of NMD during cellular 
responses to stress
Cellular stress activates widespread changes in gene 
expression that allow cells to adapt to challenging condi-
tions. One mechanism that enables this response is the 
inhibition of NMD (Table  1). Cellular stresses such as 
amino acid deprivation, hypoxia and endoplasmic retic-
ulum (ER) stress induce phosphorylation of the transla-
tion initiation factor eIF2α, which in turn causes NMD 
repression and the stabilization and increased expression 
of critical stress response factors such as ATF4, ATF3, 
CHOP, and IRE1α [70, 73, 131–136]. NMD is also attenu-
ated in response to an increase in intracellular calcium 
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levels as well as persistent DNA damage [137 AN and 
ZY, unpublished]. By controlling the expression of spe-
cific genes, this dynamic regulation of NMD serves as 
an adaptive response to cope with cellular stress and 
promote survival. When the environmental insults are 
too severe, NMD also contributes to apoptosis. An early 
event during apoptosis is the cleavage of UPF1, which 
generates a dominant negative peptide fragment that sti-
fles NMD activity [138]. The resulting reduction in NMD 
activity allows for the upregulation of several pro-apop-
totic NMD target genes including GADD45α, GADD45β, 
BAK1, GAS5, DAP3, and DUSTP2, leading to cell death 
[138, 139]. GADD45α, which acts in the MAP kinase 
pathway, has also been proposed to be the key target that 
triggers apoptosis when NMD is disrupted in the absence 
of exogenous stress [140].
The observations that NMD is suppressed in response 
to a number of cellular stresses raises the question of how 
abnormal RNAs—which are often generated during gene 
expression—are dealt with during intervals of reduced 
NMD activity. One possibility is that the benefits of the 
expression of stress response genes after NMD attenua-
tion outweigh the risks of the lack of RNA surveillance. 
It is also possible that cells retain residual NMD activ-
ity after stress, which is sufficient for RNA surveillance. 
During these intervals of low NMD activity, the activa-
tion of an autoregulatory circuit that leads to increased 
mRNA stability of NMD factors—which are normally 
targeted by NMD—rapidly restores NMD activity to 
appropriate levels once cellular conditions improve [74, 
91, 141]. The discovery of alternative branches of the 
NMD pathway that are apparently independent of UPF2, 
UPF3, or the EJC introduces the possibility that when one 
branch of NMD is suppressed other branches still remain 
active and degrade aberrant transcripts [46, 142, 143]. In 
support of this idea, the activity of the UPF2-dependent 
branch of NMD is diminished during myogenesis but 
an alternative, UPF2-independent branch is stimulated, 
allowing both for increased expression of the NMD target 
myogenin and continued degradation of mutant mRNA 
transcripts [112]. An additional mechanism to cope with 
reduced NMD activity is autophagy, which purges cells 
of the mutated, misfolded, and aggregated proteins that 
accumulate in NMD-deficient cells [144].
NMD and human disease
Nonsense-mediated RNA decay and its regulation influ-
ence the development of human disease. While some dis-
ease phenotypes are exacerbated by the effects of NMD, 
others are suppressed by them, making NMD a “double-
edged sword”. One example where NMD contributes to 
disease is β-thalassemia, which is often caused by muta-
tions in the β-globin gene that generate a nonsense 
mRNA. Most recessive forms of β-thalassemia result 
from nonsense mutations in the first or second exon of 
the β-globin gene, with the corresponding mRNAs being 
targeted for degradation by NMD [145–147]. In these 
cases, the unaffected allele is still able to be expressed but 
the amount of protein produced is unable to compen-
sate for loss of function of the mutant allele. Mutations 
Table 2 Small molecules that inhibit NMD efficiency
Compound Mechanism References
NMD inhibitors
 PI3K-like kinase inhibitors (e.g. caffeine, wortmannin) Inhibits SMG1 kinase activity [171, 172]
 NMDI1 Disrupts the interaction between SMG5 and Upf1 [174]
 NMDI14 Disrupts the interaction between SMG7 and Upf1 [158]
 Patemine A Inhibits the NMD function of eIF4A3 [23]
 5-azacytidine Promotes expression of c-Myc, which represses NMD [175]
 Cardiac glycosides (e.g. digoxin, ouabain) Increase cytoplasmic calcium, which represses NMD [137]
Translation inhibitors
 Cyclohexamide Inhibits translation [95]
 Emetine Inhibits translation [95]
 Puromycin Inhibits translation [95]
 Anisomycin Inhibits translation [95]
Translation modifiers
 Suppressor tRNAs Change stop codons into amino acid-encoding codons [164–166]
 PTC-124 Promotes stop codon read-through [167]
 Aminoglycosides Promotes stop codon read-through [168, 169]
 Amlexanox Promotes stop codon read-through [170]
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that occur in the final exon of β-globin evade degrada-
tion and consequently are translated normally. However, 
the resulting truncated proteins have dominant negative 
activity that interferes with normal hemoglobin function 
[145].
Numerous other genetic diseases, including cystic 
fibrosis, polycystic kidney disease, and muscular dystro-
phy, are also caused by PTCs that trigger NMD of tar-
get mRNAs [145, 147]. Interestingly, different subtypes 
of muscular dystrophy can result from mis-expression 
of distinct genes that are associated with NMD. Duch-
enne’s muscular dystrophy results from loss of function 
of dystrophin, which can occur when mutations in the 
gene generate a PTC that targets the transcript for NMD. 
Facioscapulohumeral muscular dystrophy results from 
the misexpression of the DUX4 transcription factor in 
muscle. DUX4 is normally a substrate for NMD, but its 
misexpression in muscle leads to the inhibition of NMD, 
resulting in a regulatory feedback loop that further sta-
bilizes the DUX4 transcript, leading to cellular toxicity 
[148].
Certain neurodevelopmental disorders are closely con-
nected with dysregulation of NMD. Mutations in the 
NMD factor UPF3B have been found to cause syndromic 
and nonsyndromic intellectual disability (ID) [101, 102, 
104, 106]. UPF3B mutations are also associated with a 
spectrum of disorders including attention-deficit hyper-
activity disorder, autism and schizophrenia [102–104]. 
Dysregulation of other NMD factors such as UPF2 and 
SMG6, is also associated with various forms of ID [102].
Aberrant NMD also is associated with inflammation 
and cancer. Deletion of one allele of the NMD kinase 
SMG1 in a mouse model results in chronic inflammation 
as well as cancer predisposition [3]. Mutations in UPF1 
have been identified in inflammatory myofibroblastic 
tumors (IMT) [149]. In IMT, decreased NMD function 
leads to increased expression of the transcript for the 
NIK protein kinase, which activates the NFkB pathway 
and promotes cytokine expression and inflammatory 
infiltrates [149]. Inhibition of NMD can cause chronic 
activation of the immune response, leading to autoim-
munity [150]. Loss of function or overexpression of NMD 
factors have also been found to be associated with several 
other cancer types, including pancreatic cancer and neu-
roblastoma [151–154]. Deregulation of NMD contrib-
utes to tumorigenesis likely due to aberrant expression of 
oncogenes and tumor suppressor genes with PTCs [151, 
155, 156].
Although decreased NMD efficiency can cause human 
disease and contribute to the severity of disease pheno-
types, NMD inhibition can also be a strategy for disease 
treatment. Inhibiting NMD may alleviate the symptoms 
of certain genetic diseases caused by PTCs in a single 
gene—e.g. β-thalassemia, cystic fibrosis, Hurler’s syn-
drome, and Duchenne muscular dystrophy—by allowing 
expression of a mutant protein product that is partially 
functional [145]. However, this therapeutic strategy is 
limited by the ability of the truncated proteins to provide 
sufficient activity to compensate for the loss of function. 
A more promising solution may be to restore expression 
of full-length, functional proteins by combined treatment 
of NMD inhibitors (to stabilize nonsense transcripts) 
with drugs that allow stop-codon read-through. This 
strategy has been successfully used to restore full-length, 
functional proteins in a model of Hurler’s syndrome and 
in cancer cells with nonsense mutations in the p53 gene 
[157, 158]. A recent modification of this potential thera-
peutic strategy uses antisense oligonucleotides (ASOs), 
which are showing increasing promise in clinical tri-
als, rather than small-molecule drugs to repress NMD 
activity, thereby expanding the repertoire of potential 
NMD-targeted therapeutic strategies [159]. Interest-
ingly, increasing NMD activity, such as by overexpress-
ing UPF1, can alleviate the phenotypes of amyotrophic 
lateral sclerosis (ALS) in both in vitro and in vivo mod-
els. A large fraction of ALS is caused by aberrant expres-
sion of TDP43, which deregulates splicing and generates 
many NMD targets [160, 161]. The observed effects of 
UPF1 overexpression suggest that NMD enhancers may 
be effective in treating certain forms of ALS and raise the 
possibility that a similar principle may apply to other dis-
orders caused by aberrant RNA processing.
Due to the presence of a higher level of nonsense 
mRNAs caused by mutations and genomic instability in 
cancer cells, inhibition of NMD may cause accumulation 
of mutant proteins and activation of the unfolded pro-
tein response, leading to heightened cell death. Inhibition 
of NMD can also promote the expression of novel anti-
gens on tumor cells, due to the translation of nonsense 
mRNAs generated by frameshift mutations or aberrant 
splicing [162, 163]. For these reasons, there has been a 
strong interest in developing small molecules to inhibit 
NMD activity (Table  2). Compounds such as cyclohex-
imide and puromycin abrogate NMD by inhibiting trans-
lation, and other reagents that modify the specificity or 
efficacy of translation termination—suppressor tRNAs, 
aminoglycosides, PTC124, amlexanox—are also capa-
ble of stabilizing nonsense transcripts [95, 164–170]. 
Wortmannin and caffeine also inhibit NMD by decreas-
ing SMG1 enzymatic activity, but these inhibitors are 
limited as tools because they also affect other PI3K 
family members such as ATM, ATR and DNA-PK [171, 
172]. Inhibitors of SMG1 kinase activity with improved 
potency and selectivity, such as pyrimidine deriviatives, 
have been identified and shown to substantially dimin-
ish UPF1 phosphorylation in  vitro and in cells [173]. 
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Recently, other potent small molecule inhibitors selective 
for SMG1 kinase have been identified to inhibit UPF1 
phosphorylation in cells and in mouse tumor xenograft 
models, where they promote anti-tumor efficacy (JMB, 
unpublished). Inhibitors to NMD factors other than 
SMG1 have also been reported. For example, patem-
ine A was found to repress NMD activity by inhibiting 
the NMD function of eIF4AIII, whereas NMDI-1 blocks 
NMD by preventing the interaction between SMG5 
and UPF1 [23, 174]. NMDI-14 was identified in a com-
putational screen for molecules that physically prevent 
the interaction of SMG7 with UPF1 [158]. Promisingly, 
NMDI-1 and particularly NMDI-14 potently repress 
NMD at low concentrations with minimal cellular tox-
icity [158, 174]. In addition, the approved drugs 5-aza-
cytidine and cardiac glycosides such as ouabain and 
digitoxin were recently found to inhibit NMD by upregu-
lating Myc or by increasing intracellular calcium, respec-
tively [137, 175]. These findings point to the potential of 
NMD-based therapeutic intervention by directly inhib-
iting NMD factors, or indirectly affecting the cellular 
microenvironment.
Perspectives
Nonsense-mediated RNA decay, initially discovered as 
a quality control mechanism that targeted mutant tran-
scripts for degradation, is now widely appreciated as a 
key mechanism that regulates gene expression. NMD 
plays a crucial role in multiple cellular processes, includ-
ing development, differentiation and disease physiology. 
While the main factors that drive NMD have been iden-
tified, many opportunities remain to fill in gaps in our 
understanding of NMD target selection and its impact 
on cell biology. A major area of ongoing NMD research 
will concern the complex regulatory networks that gov-
ern NMD activity in developmental and tissue-specific 
contexts. In addition to uncovering new pathways or 
processes where NMD is dynamically regulated, puta-
tive NMD transcripts must be validated and their effects 
on cell biology elucidated. Work discussed in this review 
has begun to address this challenge. The contribution of 
NMD to disease states, particularly neurological disor-
ders and cancer will constitute another major direction 
of NMD research. The discovery of novel inhibitors—and 
potentially also enhancers—of the NMD pathway provide 
the possibility for therapeutic intervention with genetic 
diseases, neurological disorders, and cancer. NMD inhibi-
tion by chemical or genetic means has been demonstrated 
to restore expression of proteins in vitro, but the viability 
of these strategies in vivo—including in humans—remains 
to be tested. Furthering this promising work is paramount 
to applying our ever-expanding understanding of NMD to 
the treatment of human disease.
Authors’ contributions
All authors read and approved the final manuscript.
Author details
1 Department of Cell Biology & Physiology, Washington University School 
of Medicine, Campus Box 8228, 660 S. Euclid Ave., St. Louis, MO 63110, USA. 
2 Department of Oncology Research, Amgen, South San Francisco, CA 94080, 
USA. 
Acknowledgements
We apologize to colleagues whose work is not cited due to space limitation. 
Z.Y. is supported by a NIH Grant (R01GM098535), an American Cancer Society 
Research Scholar Grant (RSG-13-212-01-DMC) and a Siteman Investment Pro-
gram Grant (4036) from the Siteman Cancer Center of Washington University.
Competing interests
The authors declare that they have no competing interests. J.M.B. is an 
employee of Amgen, Inc.
Availability of data and materials
Data sharing not applicable to this article as no datasets were generated or 
analyzed during the current study.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
Received: 5 January 2017   Accepted: 12 May 2017
References
 1. Mcllwain DR, Pan Q, Reilly PT, Elia AJ, McCracken S, Wakeham AC, 
Itie-Youten A, Blencowe BJ, Mak TW. SMG1 is required for embryo-
genesis and regulates diverse genes via alternative splicing cou-
pled to nonsense-mediated mRNA decay. Proc Natl Acad Sci USA. 
2010;107:12186–91.
 2. Medghalchi SM, Frischmeyer PA, Mendell JT, Kelly AG, Lawler AM, 
Dietz HC. Rent1, a trans-effector of nonsense-mediated mRNA decay, 
is essential for mammalian embryonic viability. Hum Mol Genet. 
2001;10:99–105.
 3. Roberts TL, Ho U, Luff J, Lee CS, Apte SH, MacDonald KP, Raggat LJ, 
Pettit AR, Morrow CA, Waters MJ, et al. SMG1 haploinsufficiency predis-
poses to tumor formation and inflammation. Proc Natl Acad Sci USA. 
2013;110:E285–94.
 4. Thoren LA, Nørgaard GA, Weischenfeldt J, Waage J, Jakobsen JS, Dam-
gaard I, Bergström FC, Blom AM, Borup R, Bisgaard HC, et al. UPF2 is a 
critical regulator of liver development, function and regeneration. PLoS 
ONE. 2010;5(7):e11650.
 5. Weischenfeldt J, Damgaard I, Bryder D, Theilgaard-Monch K, Thoren LA, 
Nielsen FC, Jacobsen SE, Nerlov C, Porse BT. NMD is essential for hemat-
opoietic stem and progenitor cells and for eliminating by-products of 
programmed DNA rearrangements. Genes Dev. 2008;22:1381–96.
 6. Li T, Shi Y, Wang P, Guachalla LM, Sun B, Joerss T, Chen YS, Groth 
M, Krueger A, Platzer M, et al. Smg6/Est1 licenses embryonic stem 
cell differentiation via nonsense-mediated mRNA decay. EMBO J. 
2015;34:1630–47.
 7. Shum EY, Jones SH, Shao A, Dumdie J, Krause MD, Chan WK, Lou CH, 
Espinoza JL, Song HW, Phan MH, et al. The antagonistic gene paralogs 
UPF3a and UPF3b govern nonsense-mediated RNA decay. Cell. 
2016;165:382–95.
 8. Anastasaki C, Longman D, Capper A, Patton EE, Caceres JF. Dhx34 and 
Nbas function in the NMD pathway and are required for embryonic 
development in zebrafish. Nucleic Acids Res. 2011;39:3686–94.
 9. Wittkopp N, Huntzinger E, Weiler C, Saulière J, Schmidt S, Sonawane M, 
Izaurralde E. Nonsense-mediated mRNA decay effectors are essential 
for zebrafish embryonic development and survival. Mol Cell Biol. 
2009;29:3517.
Page 9 of 12Nickless et al. Cell Biosci  (2017) 7:26 
 10. Lykke-Andersen S, Jensen TH. Nonsense-mediated mRNA decay: an 
intricate machinery that shapes transcriptomes. Nat Rev Mol Cell Biol. 
2015;16:665–77.
 11. Weischenfeldt J, Waage J, Tian G, Zhao J, Damgaard I, Jakobsen JS, 
Kristiansen K, Krough A, Wang J, Porse BT. Mammalian tissues defective 
in nonsense-mediated mRNA decay display highly aberrant splicing 
patterns. Genome Biol. 2012;13:R35.
 12. Lejeune F. Nonsense-mediated mRNA decay at the crossroads of many 
cellular pathways. BMB Rep. 2017;50:175–85.
 13. He F, Jacobson A. Nonsense-mediated mRNA decay: degradation 
of defective transcripts is only part of the story. Annu Rev Genet. 
2015;49:339–66.
 14. Losson R, Lacroute F. Interference of nonsense mutations with eukary-
otic messenger RNA stability. Proc Natl Acad Sci USA. 1979;76:5134–7.
 15. Pulak R, Anderson P. mRNA surveillance by the Caenorhabditis elegans 
smg genes. Genes Dev. 1993;7:1885–97.
 16. Le Hir H, Izaurralde E, Maquat LE, Moore MJ. The spliceosome deposits 
multiple proteins 20–24 nucleotides upstream of mRNA exon–exon 
junctions. EMBO J. 2000;19:6860–9.
 17. Le Hir H, Gatfield D, Izaurralde E, Moore MJ. The exon–exon junc-
tion complex provides a binding platform for factors involved 
in mRNA export and nonsense-mediated mRNA decay. EMBO J. 
2001;20:4987–97.
 18. Gehring NH, Neu-Yilik G, Schell T, Hentze MW, Kulozik AE. Y14 and 
hUPF3b form an NMD-activating complex. Mol Cell. 2003;11:939–49.
 19. Viegas MH, Gehring NH, Breit S, Hentze MW, Kulozik AE. The abundance 
of RNPS1, a protein component of the exon junction complex, can 
determine the variability in efficiency of the nonsense mediated decay 
pathway. Nucleic Acids Res. 2007;35:4542–51.
 20. Singh KK, Wachsmuth L, Kulozik AE, Gehring NH. Two mammalian 
MAGOH genes contribute to exon junction complex composition and 
nonsense-mediated decay. RNA Biol. 2013;10:1291–8.
 21. Steckelberg A, Boehm V, Gromadzka AM, Gehring NH. CWC22 connects 
pre-mRNA splicing and exon junction complex assembly. Cell Rep. 
2012;2:454–61.
 22. Kim VK, Yong J, Kataoka N, Abel L, Diem MD, Dreyfuss G. The Y14 protein 
communicates to the cytoplasm the position of exon–exon junctions. 
EMBO J. 2001;20:2062–8.
 23. Dang Y, Low WK, Xu J, Gehring NH, Dietz HC, Romo D, Liu JO. Inhibi-
tion of nonsense-mediated mRNA decay by the natural product 
pateamine A through eukaryotic initiation factor 4AIII. J Biol Chem. 
2009;284:23613–21.
 24. Palacios IM, Gatfield D, St Johnston D, Izaurralde E. An eIF4AIII-contain-
ing complex required for mRNA localization and nonsense-mediated 
mRNA decay. Nature. 2004;427:737–57.
 25. Singh G, Jakob S, Kleedehn MG, Lykke-Andersen J. Communication 
with the exon-junction complex and activation of nonsense-mediated 
decay by human Upf proteins occur in the cytoplasm. Mol Cell. 
2007;27:780–92.
 26. Bono F, Ebert J, Unterholzner L, Güttler T, Izaurralde E, Conti E. Molecular 
insights into the interaction of PYM with the Mago-Y14 core of the 
exon junction complex. EMBO Rep. 2004;5:304–10.
 27. Lykke-Andersen J, Mei-Di S, Steitz JA. Communication of the position 
of exon–exon junctions to the mRNA surveillance machinery by the 
protein RNPS1. Science. 2001;293:1836–9.
 28. Nagy E, Maquat LE. A rule for termination-codon position within intron-
containing genes: when nonsense affects RNA abundance. Trends 
Biochem Sci. 1998;23:198–9.
 29. Singh G, Rebbapragada I, Lykke-Andersen J. A competition between 
stimulators and antagonists of Upf complex recruitment governs 
human nonsense-mediated mRNA decay. PLoS Biol. 2008;6:e111.
 30. Ohnishi T, Yamashita A, Kashima I, Schell T, Anders KR, Grimson A, 
Hachiya T, Hentze MW, Anderson P, Ohno S. Phosphorylation of hUPF1 
induces formation of mRNA surveillance complexes containing hSMG-5 
and hSMG-7. Mol Cell. 2003;12:1187–200.
 31. Okada-Katsuhata Y, Yamashita A, Kutsuzawa K, Izumi N, Hirahara F, 
Ohno S. N- and C-terminal UPF1 phosphorylations create binding 
platforms for SMG-6 and SMG-5:SMG-7 during NMD. Nucleic Acids Res. 
2012;40:1251–66.
 32. Loh B, Jonas S, Izaurralde E. The SMG5-SMG7 heterodimer 
directly recruits the CCR4-NOT deadenylase complex to mRNAs 
containing nonsense codons via interaction with POP2. Genes Dev. 
2013;27:2125–38.
 33. Unterholzner L, Izaurralde E. SMG7 acts as a molecular link between 
mRNA surveillance and mRNA decay. Mol Cell. 2004;16:587–96.
 34. Cho H, Han S, Choe J, Park SG, Choi SS, Kim YK. SMG5-PNRC2 is 
functionally dominant compared with SMG5-SMG7 in mammalian 
nonsense-mediated mRNA decay. Nucleic Acids Res. 2013;41:1319–28.
 35. Lejeune F, Li X, Maquat LE. Nonsense-mediated mRNA decay in mam-
malian cells involves decapping, deadenylation, and exonucleolytic 
activities. Mol Cell. 2003;12:675–87.
 36. Lykke-Andersen J. Identification of a human decapping complex asso-
ciated with the hUpf proteins in nonsense-mediated decay. Mol Cell 
Biol. 2002;22:8114–21.
 37. Chen CY, Shyu AB. Rapid deadenylation triggered by a nonsense 
codon precedes decay of the RNA body in a mammalian cytoplasmic 
nonsense-mediated decay pathway. Mol Cell Biol. 2003;23:4805–13.
 38. Coullet P, Grange T. Premature termination codons enhance mRNA 
decapping in human cells. Nucleic Acids Res. 2004;32:488–94.
 39. Yamashita A, Chang TC, Yamashita Y, Zhu W, Zhong Z, Chen CY, Shyu 
AB. Concerted action of poly(A) nucleases and decapping enzyme in 
mammalian mRNA turnover. Nat Struct Mol Biol. 2005;12:1054–63.
 40. Huntzinger E, Kashima I, Fauser M, Sauliere J, Izaurralde E. SMG6 is 
the catalytic endonuclease that cleaves mRNAs containing nonsense 
codons in metazoans. RNA. 2008;14:2609–17.
 41. Eberle AB, Lykke-Andersen S, Muhlemann O, Jensen TH. SMG6 pro-
motes endonucleolytic cleavage of nonsense mRNA in human cells. 
Nat Struct Mol Biol. 2009;16:49–55.
 42. Lykke-Andersen S, Chen Y, Ardal BR, Lilje B, Waage J, Sandelin A, Jensen 
TH. Human nonsense-mediated RNA decay initiates widely by endonu-
cleolysis and targets snoRNA host genes. Genes Dev. 2014;28:2498–517.
 43. Schmidt SA, Foley PL, Jeong DH, Rymarquis LA, Doyle F, Tenenbaum 
SA, Belasco JG, Green PJ. Identification of SMG6 cleavage sites and a 
preferred RNA cleavage motif by global analysis of endogenous NMD 
targets in human cells. Nucleic Acids Res. 2015;43:309–23.
 44. Hogg JR, Goff SP. UPF1 senses 3′ UTR length to potentiate mRNA decay. 
Cell. 2010;143:379–89.
 45. Eberle AB, Stalder L, Mathys H, Orozco RZ, Muhlemann O. Posttranscrip-
tional gene regulation by spatial rearrangement of the 3′ untranslated 
region. PLoS Biol. 2008;6:e92.
 46. Buhler M, Steiner S, Mohn F, Paillusson A, Muhlemann O. EJC-independ-
ent degradation of nonsense immunoglobulin-μ mRNA depends on 3′ 
UTR length. Nat Struct Mol Biol. 2006;13:462–4.
 47. Amrani N, Ganesan R, Kervestin S, Mangus DA, Ghosh S, Jacobson A. 
A faux 3′-UTR promotes aberrant termination and triggers nonsense-
mediated mRNA decay. Nature. 2004;432:112–8.
 48. Karousis ED, Nasif S, Muhlemann O. Nonsense-mediated mRNA decay: 
novel mechanistic insights and biological impact. Wiley Interdiscip Rev 
RNA. 2016;7:661–82.
 49. Hug N, Longman D, Caceres JF. Mechanism and regulation of the non-
sense-mediated decay pathway. Nucleic Acids Res. 2016;44:1483–95.
 50. Kurosaki T, Maquat LE. Nonsense-mediated mRNA decay in humans at 
a glance. J Cell Sci. 2016;129:461–7.
 51. Baboo S, Bhushan B, Jiang H, Grovenor CR, Pierre P, Davis BG, Cook PR. 
Most human proteins made in both nucleus and cytoplasm turn over 
within minutes. PLoS ONE. 2014;9:e99346.
 52. Apcher S, Millot G, Daskalogianni C, Scherl A, Manoury B, Fahraeus R. 
Translation of pre-spliced RNAs in the nuclear compartment gener-
ates peptides for the MHC class I pathway. Proc Natl Acad Sci USA. 
2013;110:17951–6.
 53. Iborra FJ, Jackson DA, Cook PR. Coupled transcription and translation 
within nuclei of mammalian cells. Science. 2001;293:1139–42.
 54. Cheng J, Maquat LE. Nonsense codons can reduce the abundance of 
nuclear mRNA without affecting the abundance of pre-mRNA or the 
half-life of cytoplamsic mRNA. Mol Cell Biol. 1993;13:1892–902.
 55. Belgrader P, Cheng J, Zhou X, Stephenson LS, Maquat LE. Mammalian 
nonsense codons can be cis effectors of nuclear mRNA half-life. Mol 
Cell Biol. 1994;14:8219–28.
 56. Belgrader P, Maquat LE. Nonsense but not missense mutations can 
decrease the abundance of nuclear mRNA for the mouse major urinary 
protein, while both types of mutations can facilitate exon skipping. Mol 
Cell Biol. 1994;14:6326–36.
Page 10 of 12Nickless et al. Cell Biosci  (2017) 7:26 
 57. Cheng J, Belgrader P, Zhou X, Maquat LE. Introns are cis effectors of the 
nonsense-codon-mediated reduction in nuclear mRNA abundance. 
Mol Cell Biol. 1994;14:6317–25.
 58. Bhalla AD, Gudikote JP, Wang J, Chan WK, Chang YF, Olivas OR, Wilkinson 
MF. Nonsense codons trigger an RNA partitioning shift. J Biol Chem. 
2009;284:4062–72.
 59. Lozano F, Maertzdorf B, Pannell R, Milstein C. Low cytoplasmic 
mRNA levels of immunoglobulin kappa light chain genes contain-
ing nonsense codons correlate with inefficient splicing. EMBO J. 
1994;13:4617–22.
 60. Gersappe A, Pintel DJ. A premature termination codon interferes with 
the nuclear function of an exon splicing enhancer in an open reading 
frame-dependent manner. Mol Cell Biol. 1999;19:1640–50.
 61. Muhlemann O, Mock-Casagrande CS, Wang J, Li S, Custodio N, 
Carmo-Fonseca M, Wilkinson MF, Moore MJ. Precursor RNAs harboring 
nonsense codons accumulate near the site of transcription. Mol Cell. 
2001;8:33–43.
 62. Buhler M, Wilkinson MF, Muhlemann O. Intranuclear degradation of 
nonsense codon-containing mRNA. EMBO Rep. 2002;3:646–51.
 63. Kessler O, Chasin LA. Effects of nonsense mutations on nuclear and 
cytoplasmic adenine phosphoribosyltransferase RNA. Mol Cell Biol. 
1996;16:4426–35.
 64. Takeshita K, Forget BG, Scarpa A, Benz EJ. Intranuclear defect in beta- 
globin mRNA accumulation due to a premature translation termination 
codon. Blood. 1984;64:13–22.
 65. Wang J, Chang YF, Hamilton JI, Wilkinson MF. Nonsense-associated 
altered splicing: a frame-dependent response distinct from nonsense-
mediated decay. Mol Cell. 2002;10:951–7.
 66. Trcek T, Sato H, Singer RH, Maquat LE. Temporal and spatial characteri-
zation of nonsense-mediated mRNA decay. Genes Dev. 2013;27:541–51.
 67. Lewis BP, Green RE, Brenner SE. Evidence for the widespread coupling 
of alternative splicing and nonsense-mediated mRNA decay in humans. 
Proc Natl Acad Sci USA. 2003;100:189–92.
 68. Cao D, Parker R. Computational modeling and experimental analysis of 
nonsense-mediated decay in yeast. Cell. 2003;113:533–45.
 69. He F, Li X, Spatrick P, Casillo R, Dong S, Jacobson A. Genome-wide analy-
sis of mRNAs regulated by the nonsense-mediated and 5′ to 3′ mRNA 
decay pathways in yeast. Mol Cell. 2003;12:1439–52.
 70. Mendell JT, Sharifi NA, Meyers JL, Matinez-Murillo R, Dietz HC. Nonsense 
surveillance regulates expression of diverse classes of mammalian 
transcripts and mutes genomic noise. Nat Genet. 2004;36:1073–8.
 71. Wittmann J, Hol EM, Hans-Martin J. hUPF2 silencing identifies physi-
ologic substrates of mammalian nonsense-mediated mRNA decay. Mol 
Cell Biol. 2006;26:1272–87.
 72. Tani H, Imamachi N, Salam KA, Mizutani R, Ijiri K, Irie T, Yada T, Suzuki Y, 
Akimitsu N. Identification of hundreds of novel UPF1 target transcripts 
by direct determination of whole transcriptome stability. RNA Biol. 
2012;9:1370–9.
 73. Wang D, Zavadil J, Martin L, Parisi F, Friedman E, Levy D, Harding H, 
Ron D, Gardner LB. Inhibition of nonsense-mediated RNA decay by 
the tumor microenvironment promotes tumorigenesis. Mol Cell Biol. 
2011;31:3670–80.
 74. Yepiskoposyan H, Aescimann F, Nilsson D, Okoniewski M, Mühlemann 
O. Autoregulation of the nonsense-mediated mRNA decay pathway in 
human cells. RNA. 2011;17:2108–18.
 75. Rehwinkel J, Letunic I, Raes J, Bork P, Izaurralde E. Nonsense-mediated 
mRNA decay factors act in concert to regulate common mRNA targets. 
RNA. 2005;11:1530–44.
 76. Wollerton MC, Gooding C, Wagner EJ, Garcia-Blanco MA, Smith 
CW. Autoregulation of polypyrimidine tract binding protein by 
alternative splicing leading to nonsense-mediated decay. Mol Cell. 
2004;13:91–100.
 77. Ni JZ, Grate L, Donohue JP, Preston C, Nobida N, O’Brien G, Shiue L, Clark 
TA, Blume JE, Ares M Jr. Ultraconserved elements are associated with 
homeostatic control of splicing regulators by alternative splicing and 
nonsense-mediated decay. Genes Dev. 2007;21:708–18.
 78. Lareau LF, Inada M, Green RE, Wengrod JC, Brenner SE. Unproductive 
splicing of SR genes associated with high conserved and ultraconser-
ved DNA elements. Nature. 2007;446:926–9.
 79. Saltzman AL, Kim YK, Pan Q, Fagnani MM, Maquat LE, Blencowe BJ. 
Regulation of multiple core spliceosomal proteins by alternative 
splicing-coupled nonsense-mediated mRNA decay. Mol Cell Biol. 
2008;28:4320–30.
 80. Sureau A, Gattoni R, Dooghe Y, Stevenin J, Soret J. SC35 autoregulates 
its expression by promoting splicing events that destabilize its mRNAs. 
EMBO J. 2001;20:1785–96.
 81. Wilson GM, Sun Y, Sellers J, Lu H, Penkar N, Dillard G, Brewer G. Regula-
tion of AUF1 expression via conserved alternatively spliced elements in 
the 3′ untranslated region. Mol Cell Biol. 1999;19:4056–64.
 82. Malabat C, Feuerbach F, Ma L, Saveanu C, Jacquier A. Quality control of 
transcription start site selection by nonsense-mediated-mRNA decay. 
eLife. 2015;4:e06722.
 83. Belew AT, Hepler NL, Jacobs JL, Dinman JD. PRFdb: a database of com-
putationally predicted eukaryotic programmed-1 ribosomal frameshift 
signals. BMC Genom. 2008;9:339.
 84. Belew AT, Advani VM, Dinman JD. Endogenous ribosomal frameshift 
signals operate as mRNA destabilizing elements through at least two 
molecular pathways in yeast. Nucleic Acids Res. 2011;39:2799–808.
 85. Belew AT, Meskauskas A, Musalgaonkar S, Advani VM, Sulima SO, 
Kasprzak WK, Shapiro BA, Dinman JD. Ribosomal frameshifting in the 
CCR5 mRNA is regulated by miRNAs and the NMD pathway. Nature. 
2014;512:265–9.
 86. Advani VM, Belew AT, Dinman JD. Yeast telomere maintenance is 
globally controlled by programmed ribosomal frameshifting and the 
nonsense-mediated mRNA decay pathway. Translation. 2013;1:e24418.
 87. Barbosa C, Peixeiro I, Romão L. Gene expression regulation by 
upstream open reading frames and human disease. PLoS Genet. 
2013;9:e1003529.
 88. Hurt JA, Robertson AD, Burge CB. Global analyses of UPF1 binding and 
function reveal expanded scope of nonsense-mediated mRNA decay. 
Genome Res. 2013;23:1636–50.
 89. Toma KG, Rebbapragada I, Durand S, Lykke-Andersen J. Identification 
of elements in human long 3′ UTRs that inhibit nonsense-mediated 
decay. RNA. 2015;21:887–97.
 90. Bruno IG, Karam R, Huang L, Bhardwaj A, Lou CH, Shum EY, Song HW, 
Corbett MA, Gifford WD, Gecz J, et al. Identification of a microRNA that 
activates gene expression by repressing nonsense-mediated RNA 
decay. Mol Cell. 2011;42:500–10.
 91. Huang L, Lou CH, Chan W, Shum EY, Shao A, Stone E, Karam R, 
Song HW, Wilkinson MF. RNA homeostasis governed by cell type-
specific and branched feedback loops acting on NMD. Mol Cell. 
2011;43:950–61.
 92. Shetty SP, Copeland PR. Selenocysteine incorporation: a trump card in 
the game of mRNA decay. Biochimie. 2015;114:97–101.
 93. Seyedali A, Berry MJ. Nonsense-mediated decay factors are involved 
in the regulation of selenoprotein mRNA levels during selenium defi-
ciency. RNA. 2014;20:1248–56.
 94. Usuki F, Yamashita A, Fujimura M. Post-transcriptional defects of anti-
oxidant selenoenzymes cause oxidative stress under methylmercury 
exposure. J Biol Chem. 2011;286:6641–9.
 95. Carter MS, Doskow J, Morris P, Li S, Nhim RP, Sandstedt S, Wilkinson MF. 
A regulatory mechanism that detects premature nonsense codons in 
T-cell receptor transcripts in vivo is reverse by protein synthesis inhibi-
tors in vitro. J Biol Chem. 1995;270:28995–9003.
 96. Gudikote JP, Wilkinson MF. T-cell receptor sequences that elicit strong 
downregulation of premature termination codon-bearing transcripts. 
EMBO J. 2002;21:125–34.
 97. Frischmeyer-Guerrerio PA, Montgomery RA, Warren DS, Cooke SK, Lutz 
J, Sonnenday CJ, Guerrerio AL, Dietz HC. Perturbation of thymocyte 
development in nonsense-mediated decay (NMD)-deficient mice. Proc 
Natl Acad Sci USA. 2011;108:10638–43.
 98. Wong JJ, Ritchie W, Ebner OA, Selbach M, Wong JW, Huang Y, Gao D, 
Pinello N, Gonzalez M, Baidya K, et al. Orchestrated intron retention 
regulates normal granulocyte differentiation. Cell. 2013;154:583–95.
 99. Lou CH, Shao A, Shum EY, Espinoza JL, Huang L, Karam R, Wilkinson 
MF. Posttranscriptional control of the stem cell and neurogenic 
programs by the nonsense-mediated RNA decay pathway. Cell Rep. 
2014;6:748–64.
 100. Lou CH, Dumdie J, Goetz A, Shum EY, Brafman D, Liao X, Mora-Castilla 
S, Ramaiah M, Cook-Andersen H, Laurent L, et al. Nonsense-mediated 
RNA decay influences human embryonic stem cell fate. Stem Cell Rep. 
2016;6:844–57.
Page 11 of 12Nickless et al. Cell Biosci  (2017) 7:26 
 101. Tarpey PS, Raymond FL, Nguyen LS, Rodriguez J, Hackett A, Vande-
leur L, Smith R, Shoulbridge C, Edkins S, Stevens C, et al. Mutations in 
UPF3B, a member of the nonsense-mediated mRNA decay complex, 
cause syndromic and nonsyndromic mental retardation. Nat Genet. 
2007;39:1127–33.
 102. Nguyen LS, Kim HG, Rosenfeld JA, Shen Y, Gusella JF, Lacassie Y, Layman 
LC, Shaffer LG, Gécz J. Contribution of copy number variants involving 
nonsense-mediated mRNA decay pathway genes to neuro-develop-
mental disorders. Hum Mol Genet. 2013;22:1816–25.
 103. Addington AM, Gauthier J, Piton A, Hamdan FF, Raymond A, Gogtay 
N, Miller R, Tossell J, Bakalar J, Inoff-Germain G, et al. A novel frameshift 
mutation in UPF3B identified in brothers affected with childhood 
onset schizophrenia and autism spectrum disorders. Mol Psychiatry. 
2011;16:238–9.
 104. Laumonnier F, Shoubridge C, Antar C, Nguyen LS, Van Esch H, Kleefstra 
T, Briault S, Fryns JP, Hamel B, Chelly J, et al. Mutations of the UPF3B 
gene, which encodes a protein widely expressed in neurons, are associ-
ated with nonspecific mental retardation with or without autism. Mol 
Psychiatry. 2010;15:767–76.
 105. Jolly LA, Homan CC, Jacob R, Barry S, Gécz J. The UPF3B gene, impli-
cated in intellectual disability, autism, ADHD and childhood onset 
schizophrenia regulates neural progenitor cell behaviour and neuronal 
outgrowth. Hum Mol Genet. 2013;22:4673–87.
 106. Xu X, Zhang L, Tong P, Xun G, Su W, Xiong Z, Zhu T, Zheng Y, Luo S, Pan 
Y, et al. Exome sequencing identifies UPF3B as the causative gene for 
a Chinese non-syndrome mental retardation pedigree. Clin Genet. 
2013;83:560–4.
 107. Alrahbeni T, Sartor F, Anderson J, Miedzybrodzka Z, McCaig C, Muller B. 
Full UPF3B function is critical for neuronal differentiation of neural stem 
cells. Mol Brain. 2015;8:33.
 108. Giorgi C, Yeo GW, Stone ME, Katz DB, Burge C, Turrigiano G, Moore 
MJ. The EJC factor eIF4AIII modulates synaptic strength and neuronal 
protein expression. Cell. 2007;130:179–91.
 109. Colak D, Ji SJ, Porse BT, Jaffrey SR. Regulation of axon guidance by compart-
mentalized nonsense-mediated mRNA decay. Cell. 2013;153:1252–65.
 110. Eom T, Zhang C, Wang H, Lay K, Fak J, Noebels JL, Darnell RB. NOVA-
dependent regulation of cryptic NMD exons controls synaptic protein 
levels after seizure. elife. 2013;2:e00178.
 111. Kim YK, Furic L, Desgroseillers L, Maquat LE. Mammalian staufen1 
recruits UPF1 to specific mRNA 3′UTRs so as to elicit mRNA decay. Cell. 
2005;120:195–208.
 112. Gong C, Kim YK, Woeller CF, Tang Y, Maquat LE. SMD and NMD are 
competitive pathways that contribute to myogenesis: effects on PAX3 
and myogenin mRNAs. Genes Dev. 2009;23:54–66.
 113. Park E, Maquat LE. Staufen-mediated mRNA decay. Wiley Interdiscip Rev 
RNA. 2013. doi:10.1002/wrna.1168.
 114. Balistreri G, Horvath P, Schweingruber C, Zünd D, Mclnerney G, Merits 
A, Mühlemann O, Azzalin C, Helenius A. The host nonsense-mediated 
mRNA decay pathway restricts mammalian RNA virus replication. Cell 
Host Microbe. 2014;16:403–11.
 115. Garcia D, Garcia S, Voinnet O. Nonsense-mediated decay serves as 
a general viral restriction mechanism in plants. Cell Host Microbe. 
2014;16:391–402.
 116. Mocquet V, Neusiedler J, Rende F, Cluet D, Robin JP, Terme JM, Duc 
Dodon M, Wittmann J, Morris C, Le Hir H, Ciminale V, Jalinot P. The 
human T-lymphotropic virus type 1 tax protein inhibits nonsense-
mediated mRNA decay by interacting with INT6/EIF3E and UPF1. J Virol. 
2012;86:7530–43.
 117. Nakano K, Ando T, Yamagishi M, Yokoyama K, Ishida T, Ohsugi T, Tanaka 
Y, Brighty DW, Watanabe T. Viral interference with host mRNA surveil-
lance, the nonsense-mediated mRNA decay (NMD) pathway, through 
a new function of HTLV-1 Rex: implications for retroviral replication. 
Microbes Infect. 2013;15:491–505.
 118. Weil JE, Beemon KL. A 3′ UTR sequence stabilizes termination codons in 
the unspliced RNA of Rous sarcoma virus. RNA. 2006;12:102–10.
 119. Quek BL, Beemon K. Retroviral strategy to stabilize viral RNA. Curr Opin 
Microbiol. 2014;18:78–82.
 120. Ramage HR, Kumar GR, Verschueren E, Johnson JR, Von Dollen J, 
Johnson T, Newton B, Shah P, Horner J, Krogran NJ, et al. A combined 
proteomics/genomics approach links hepatitis C virus infection with 
nonsense-mediated mRNA decay. Mol Cell. 2015;57:329–40.
 121. Taft RJ, Pheasant M, Mattick JS. The relationship between non-
protein-coding DNA and eukaryotic complexity. BioEssays. 
2007;29:288–99.
 122. Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A, Tanzer 
A, Lagarde J, Lin W, Schlesinger F, et al. Landscape of transcription in 
human cells. Nature. 2012;489:101–8.
 123. Batista PJ, Chang HY. Long noncoding RNAs: cellular address codes in 
development and disease. Cell. 2013;152:1298–307.
 124. Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, Huarte M, Zuk 
O, Carey BW, Cassady JP, et al. Chromatin signature reveals over a thou-
sand highly conserved large non-coding RNAs in mammals. Nature. 
2009;458:223–7.
 125. Ingolia NT, Lareau LF, Weissman JS. Ribosome profiling of mouse 
embryonic stem cells reveals the complexity and dynamics of mam-
malian proteomes. Cell. 2011;147:789–802.
 126. Brar GA, Yassour M, Friedman N, Regev A, Ingolia NT, Weissman JS. High-
resolution view of the yeast meiotic program revealed by ribosome 
profiling. Science. 2012;335:552–7.
 127. Chew GL, Pauli A, Rinn JL, Regev A, Schier AF, Valen E. Ribosome 
profiling reveals resemblance between long non-coding RNAs and 5′ 
leaders of coding RNAs. Development. 2013;140:2828–34.
 128. van Heesch S, van Iterson M, Jacobi J, Boymans S, Essers PB, de Bruijn 
E, Hao W, Macinnes AW, Cuppen E, Simonis M. Extensive localization 
of long noncoding RNAs to the cytosol and mono and polyribosomal 
complexes. Genome Biol. 2014;15:R6.
 129. Smith JE, Alvarez-Dominguez JR, Kline N, Huynh NJ, Geisler S, Hu W, 
Coller J, Baker KE. Translation of small open reading frames within 
unannotated RNA transcripts in Saccharomyces cerevisiae. Cell Rep. 
2014;7:1858–66.
 130. Wery M, Descrimes M, Vogt N, Dallongeville AS, Gautheret D, Morillon 
A. Nonsense-mediated decay restricts lncRNA levels in yeast unless 
blocked by double-stranded RNA structure. Mol Cell. 2016;61:379–92.
 131. Gardner LB. Hypoxic inhibition of nonsense-mediated RNA decay 
regulates gene expression and the integrated stress response. Mol Cell 
Biol. 2008;28:3729–41.
 132. Martin L, Gardner LB. Stress-induced inhibition of nonsense-mediated 
RNA decay regulates intracellular cystine transport and intracellular 
glutathione through regulation of the cystine/glutamate exchanger 
SLC7A11. Oncogene. 2015;34:4211–8.
 133. Karam R, Lou CH, Kroeger H, Huang L, Lin JH, Wilkinson MF. The 
unfolded protein response is shaped by the NMD pathway. EMBO Rep. 
2015;16:599–609.
 134. Oren YS, McClure ML, Rowe SM, Sorcher EJ, Bester AC, Manor M, Kerem 
E, Rivlin J, Zahdeh F, Mann M, Geiger T, Kerem B, et al. The unfolded pro-
tein response affects readthrough of premature termination codons. 
EMBO Mol Med. 2014;6:685–701.
 135. Gardner LB. Nonsense-mediated RNA decay regulation by cellular 
stress: implications for tumorigenesis. Mol Cancer Res. 2010;8:295–308.
 136. Sieber J, Hauer C, Bhuvanagiri M, Leicht S, Krijgsveld J, Neu-Yilik G, 
Hentze MW, Kulozik AE. Proteomic analysis reveals branch-specific 
regulation of the unfolded protein response by nonsense-mediated 
mRNA decay. Mol Cell Proteom. 2016;15:1584–97.
 137. Nickless A, Jackson E, Marasa J, Nugent P, Mercer RW, Piwnica-Worms D, 
You Z. Intracellular calcium regulates nonsense-mediated mRNA decay. 
Nat Med. 2014;20:961–6.
 138. Popp MW, Maquat LE. Attenuation of nonsense-mediated mRNA 
decay facilitates the response to chemotherapeutics. Nat Commun. 
2015;6:6632.
 139. Tani H, Torimura M, Akimitsu N. The RNA degradation pathway regu-
lates the function of GAS5 a non-coding RNA in mammalian cells. PLoS 
ONE. 2013;8:e55684.
 140. Nelson JO, Moore KA, Chapin A, Hollien J, Metzstein MM. Degradation 
of Gadd45 mRNA by nonsense-mediated decay is essential for viability. 
eLife. 2016;5:e12876.
 141. Longman D, Hug N, Keith M, Anastasaki C, Patton EE, Grimes G, Cáceres 
JF. DHX34 and NBAS form part of an autoregulatory NMD circuit that 
regulates endogenous RNA targets in human cells, zebrafish and Cae-
norhabditis elegans. Nucleic Acids Res. 2013;41:8319–31.
 142. Chan W, Huang L, Gudikote JP, Chang Y, Imam JS, MacLean JA II, 
Wilkinson MF. An alternative branch of the nonsense-mediated decay 
pathway. EMBO J. 2007;26:1820–30.
Page 12 of 12Nickless et al. Cell Biosci  (2017) 7:26 
 143. Gehring NH, Kunz JB, Neu-Yilik G, Breit S, Viegas MH, Hentze MW, Kulozik 
AE. Exon-junction complex components specify distinct routes of 
nonsense-mediated mRNA decay with differential cofactor require-
ments. Mol Cell. 2005;20:65–75.
 144. Wengrod J, Martin L, Wang D, Frischmeyer-Guerrerio P, Dietz HC, 
Gardner LB. Inhibition of nonsense-mediated RNA decay activates 
autophagy. Mol Cell Biol. 2013;33:2128–35.
 145. Holbrook JA, Neu-Yilik G, Hentze MW, Kulozik AE. Nonsense-mediated 
decay approaches the clinic. Nat Genet. 2004;2004(36):801–8.
 146. Maquat LE, Kinniburgh AJ, Rachmilewitz EA, Ross J. Unstable β-globin 
mRNA in mRNA-deficient β0 thalassemia. Cell. 1981;27:543–53.
 147. Frischmeyer PA, Dietz HC. Nonsense-mediated mRNA decay in health 
and disease. Hum Mol Genet. 1999;8:1893–900.
 148. Feng Q, Snider L, Jagannathan S, Tawil R, van der Maarel SM, Tapscott SJ, 
Bradley RK. A feedback loop between nonsense-mediated decay and 
the retrogene DUX4 in facioscapulohumeral muscular dystrophy. Elife. 
2015;4:e04996. doi:10.7554/elife.04996.
 149. Lu J, Plank TD, Su F, Shi X, Liu C, Ji Y, Li S, Huynh A, Shi C, Zhu B, et al. The 
nonsense-mediated RNA decay pathway is disrupted in inflammatory 
myofibroblastic tumors. J Clin Invest. 2016;126:3058–62.
 150. Rigby RE, Rehwinkel J. RNA degradation in antiviral immunity and 
autoimmunity. Trends Immunol. 2015;36:179–88.
 151. El-Bchiri J, Guilloux A, Dartigues P, Loire E, Mercier D, Buhard O, Sobhani 
I, de la Grange P, Auboeuf D, Praz F, et al. Nonsense-mediated mRNA 
decay impacts MSI-driven carcinogenesis and anti-tumor immunity in 
colorectal cancers. PLoS ONE. 2008;3:e2583.
 152. Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D, 
Carter SL, Cibulskis K, Hanna M, Kiezun A, et al. The genetic landscape of 
high-risk neuroblastoma. Nat Genet. 2013;45:279–84.
 153. Beheshti B, Braude I, Marrano P, Throner P, Zielenska M, Squire JA. Chro-
mosomal localization of DNA amplifications in neuroblastoma tumors 
using cDNA microarray comparative genomic hybridization. Neoplasia. 
2003;5:53–62.
 154. Liu C, Karam R, Zhou Y, Su F, Ji Y, Li G, Xu G, Lu L, Wang C, Song M, et al. 
The UPF1 RNA surveillance gene is commonly mutated in pancreatic 
adenosquamaous carcinoma. Nat Med. 2014;20:596–8.
 155. Karam R, Carvalho J, Bruno I, Graziadio C, Senz J, Huntsman D, Carneiro 
F, Seruca R, Wilkinson MF, Oliveira C. The NMD mRNA surveillance path-
way downregulates aberrant E-cadherin transcripts in gastric cancer 
cells and in CDH1 mutation carriers. Oncogene. 2008;27:4255–60.
 156. De Rosa M, Morelli G, Cesaro E, Duraturo F, Turano M, Rossi GB, Delrio 
P, Izzo P. Alternative splicing and nonsense-mediated mRNA decay in 
the regulation of a new adenomatous polyposis coli transcript. Gene. 
2007;395:8–14.
 157. Keeling KM, Wang D, Dai Y, Murugesan S, Chenna B, Clark J, Belakhov V, 
Kandasamy J, Velu SE, Baasov T, et al. Attenuation of nonsense-medi-
ated mRNA decay enhances in vivo nonsense suppression. PLoS ONE. 
2013;8:e60478.
 158. Martin L, Grigoryan A, Wang D, Wang J, Breda L, Rivella S, Cardozo T, 
Gardner LB. Identification and characterization of small molecules that 
inhibit nonsense-mediated RNA decay and suppress nonsense p53 
mutations. Cancer Res. 2014;74:3104–13.
 159. Nomakuchi TT, Rigo F, Aznarez I, Krainer AR. Antisense oligonucleotide-
directed inhibition of nonsense-mediated mRNA decay. Nat Biotechnol. 
2016;34:164–6.
 160. Barmada SJ, Ju S, Arjun A, Batarse A, Archbold HC, Peisach D, Xingli L, 
Zhang Y, Tank EMH, Qiu H. Amelioration of toxicity in neuronal models 
of amyotrophic lateral sclerosis by hUPF1. Proc Natl Acad Sci USA. 
2015;112:7821–6.
 161. Jackson KL, Dayton RD, Orchard EA, Ju S, Ringe D, Petsko GA, Maquat LE, 
Klein RL. Preservation of forelimb function by UPF1 gene therapy in a 
rat model of TDP-43-induced motor paralysis. Gene Ther. 2015;22:20–8.
 162. Gilboa E. Expression of new antigens on tumor cells by inhibiting 
nonsense-mediated mRNA decay. Immunol Res. 2013;57:44–51.
 163. Pastor F, Kolonias D, Giangrande PH, Gilboa E. Induction of tumour 
immunity by targeted inhibition of nonsense-mediated mRNA decay. 
Nature. 2010;465:227–30.
 164. Temple GF, Dozy AM, Roy KL, Kan YW. Construction of a functional 
human suppressor tRNA gene: an approach to gene therapy for beta-
thalassaemia. Nature. 1982;296:537–40.
 165. Kiselev AV, Ostapenko OV, Rogozhkina EV, Kholod NS, Seit Nebi AS, 
Baranov AN, Lesina EA, Ivashchenko TE, SabetskiĬ VA, Shavlovskiĭ MM, 
et al. Suppression of nonsense mutations in the Dystrophin gene by a 
suppressor tRNA gene. Mol Biol (Mosk). 2002;36:43–7.
 166. Buvoli M, Buvoli A, Leinwand LA. Suppression of nonsense mutations in 
cell culture and mice by multimerized suppressor tRNA genes. Mol Cell 
Biol. 2000;20:3116–24.
 167. Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P, Paushkin 
S, Patel M, Trotta CR, Hwang S, et al. PTC124 targets genetic disorders 
caused by nonsense mutations. Nature. 2007;447:87–91.
 168. Burke JF, Mogg AE. Suppression of a nonsense mutation in mammalian 
cells in vivo by the aminoglycoside antibiotics G-418 and puromycin. 
Nucleic Acids Res. 1985;13:6265–72.
 169. Keeling KM, Bedwell DM. Clinically relevant aminoglycosides can 
suppress disease-associated premature stop mutations in the IDUA 
and p53 cDNAs in a mammalian translation system. J Mol Med (Berl). 
2002;80:367–76.
 170. Gonzalez-Hilarion S, Beghyn T, Jia J, Bebreuck N, Berte G, Mamchaoui K, 
Mouly V, Gruenert DC, Déprez B, Lejeune F. Rescue of nonsense muta-
tions by amlexanox in human cells. Orphanet J Rare Dis. 2012;7:58.
 171. Yamashita A, Ohnishi T, Kashima I, Taya Y, Ohno S. Human SMG-1, a 
novel phosphatidylinositol 3-kinase-related protein kinase, associ-
ates with components of the mRNA surveillance complex and is 
involved in the regulation of nonsense-mediated decay. Genes Dev. 
2001;15:2215–28.
 172. Denning G, Jamieson L, Maquat LE, Thompson EA, Fields AP. Cloning 
of a novel phosphatidylinositol kinase-related kinase: characteriza-
tion of the human SMG-1 RNA surveillance protein. J Biol Chem. 
2001;276:22709–14.
 173. Gopalsamy A, Bennett EM, Shi M, Zhang WG, Bard J, Yu K. Identification 
of pyrimidine derivatives as hSMG-1 inhibitors. Bioorg Med Chem Lett. 
2012;22:6636–41.
 174. Durand S, Cougot N, Mahuteau-Betzer F, Nguyen CH, Grierson DS, 
Bertrand E, Tazi J, Lejeune F. Inhibition of nonsense-mediated mRNA 
decay (NMD) by a new chemical molecule reveals the dynamic of NMD 
factors in P-bodies. J Cell Biol. 2007;178:1145–60.
 175. Bhuvanagiri M, Lewis J, Putzker K, Becker JP, Leicht S, Krijgsveld J, 
Batra R, Turnwald B, Jovanovic B, Hauer C, et al. 5-azacytidine inhibits 
nonsense-mediated decay in a MYC-dependent fashion. EMBO Mol 
Med. 2014;6:1593–609.
 176. Peccarelli M, Kebarra BW. Regulation of natural mRNAs by the non-
sense-mediated mRNA decay pathway. Eukaryot Cell. 2014;13:1126–35.
